CMO Dr. Andrew Hertler on the Recent FDA ODAC Meeting
New Century Health, a national leader in specialty care management, is proud to provide comprehensive oncol...
Evidence-Based Oncology interviews our CMO about mismatches between drug costs and efficacy.
GDMT, or guideline-directed medical therapy, means taking the right medication at the optimal doses to treat cardiovascular problems. Yet these medications are chronically underused.
Every day, cardiologists make decisions about what is the most appropriate test, therapy, or procedure for their patients. But then COVID-19 came along. Have the rules of the game changed?
Our CMO speaks with Managed Care Executive about the promise and perils of genomic testing.
Modern Healthcare spoke with NCH's Dr. Andrew Hertler about problems in the FDA's approval process.
Our CMO speaks with Formulary Watch about the challenges of high--cost drugs with marginal benefit.
The addition of Vital Decisions’ specialized patient engagement services expected to position New Century Health to accelerate growth, improve patient care quality and increase margins.
The FDA's Aduhelm approval was highly controversial, but not as surprising for those who follow the oncology drug pipeline.
Our chief medical officer highlights noteworthy research and results from clinical oncology's premier event.
New Century Health, a national leader in specialty care management, is proud to provide comprehensive oncology specialty management services to Neighborhood Health Plan of Rhode Island.
Our CMO Dr. Andrew Hertler speaks with HFMA about the role of telehealth in oncology care today.
Senior Medical Director Fernando Villacian lays out the key tenets of an effective cardiovascular management program.
In this podcast series we explore the trends and forces behind the two leading causes of death in the United States: cancer and heart disease.
Our senior medical director speaks with Journal of Clinical Pathways about preventing inappropriate use in cardiology.
New Century Health announced that 2020 was the largest membership growth year in the 19-year history of the company.
A new research effort aims to gauge whether certain groups of patients receive high-value therapies at lower rates than others.
Payer strains now top the list of stressors facing oncologists, with prior authorization as the most-cited source of that payer stress.
Evolent Health, Parent Company of New Century Health, Names Kim Keck to Board of Directors. Announces Cheryl Scott to Serve as Lead Independent Director.
NCH's approach to more appropriate use of myeloid growth factor provides a playbook for how to change prescribing patterns.
New Century Health recently convened health plan executives, industry experts and oncologists from across the nation to discuss the confluence of forces shaping oncology care in 2021 and beyond.